<DOC>
	<DOCNO>NCT00986349</DOCNO>
	<brief_summary>The main objective study demonstrate safety efficacy Gastrointestinal ( GI ) EndoBarrier glycemic control diabetes subject Type 2 diabetes .</brief_summary>
	<brief_title>Study EndoBarrier Liner Treatment Type 2 Diabetes Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects Age &gt; 18 year ≤ 55 year Male Female Subjects Type 2 Diabetes treat ≤10 year oral diabetic medication Subjects HbA1C &gt; 7.5 ≤ 10.0 % Subjects BMI &gt; 26 &lt; 50 Subjects willing comply study requirement Subjects sign informed consent form Women postmenopausal , surgically sterile oral contraceptive agree remain oral contraceptive least twentyfour ( 24 ) week implant duration trial participation agree become pregnant trial . Subjects diagnose Type 1 Diabetes Mellitus history ketoacidosis Subjects require insulin Subjects probable insulin production failure ( fast C Peptide serum &lt; 1ng/mL ) Subjects autoimmune disease evidence positive antiGAD blood test Subjects weight loss &gt; 4.5 Kg ( 10 lb ) within 12 Weeks screening Subjects require prescription anticoagulation therapy Subjects history iron deficiency and/or iron deficiency anemia Subjects history abnormality GI tract Subjects symptomatic gallstone kidney stone time screening Subjects know infection Subjects history coagulopathy , upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasia Subjects mentally retard emotionally unstable , exhibit psychological characteristic , opinion Investigator , make Subject poor candidate device placement clinical trial participation Subjects previous GI surgery could affect ability place device function implant Subjects unable discontinue NSAIDs ( nonsteroidal antiinflammatory drug ) implant period Subjects active H. pylorus ( Note : Subjects may enrol prior history H. Pylori successfully treat ) Subjects receive weight loss medication Meridia , Xenical , counter weight loss medication Subject Family history know diagnosis preexist symptom systemic lupus erythematosus , scleroderma autoimmune connective tissue disorder Subjects active uncontrolled GERD Subjects know history substance abuse Subjects participate another ongoing investigational clinical trial Subjects take corticosteroid drug know affect GI motility ( i.e . Reglan )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>GI Dynamics</keyword>
	<keyword>EndoBarrier</keyword>
</DOC>